Frequency, Risk‐Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database
Authors:
- Katja von HoffKHKatja von Hoff
- Angela EmserAEAngela Emser
- Isabella ZwienerIZIsabella Zwiener
- 27 July 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (6) , 978-985
Abstract
Purpose: To analyze the frequency, prognostic factors, and outcome of children with atypical teratoid/rhabdoid tumors (AT/RT), a rare and highly malignant embryonal brain tumor.Materials and Methods: Clinical data of patients diagnosed between 1988 and 2004 with AT/RT who were registered to the German HIT trial center, were correlated with outcome. Patient numbers for AT/RT were compared to numbers for primitive neuroectodermal tumors and medulloblastomas (PNET/MB) registered to the population‐based HIT trials.Results: We identified 56 patients with the centrally confirmed histopathological diagnosis of AT/RT with a median age of 1.2 years (range, 0.1–14.0 years). The AT/RT:PNET/MB ratio was 1:12.2 for all children, and 1:1.5 for children younger than 1 year at diagnosis. Three‐year overall survival (OS) and event‐free survival (EFS) for all patients were 22% and 13%, respectively. Eight patients (14%) are considered long‐term event‐free survivors (follow‐up 1.4–10.6 years). By univariable analyses, younger age, metastatic disease, infratentorial location, and less than complete remission at the end of chemotherapy were identified as negative influencing factors for OS. By multivariable analyses, younger age (OS, EFS) and metastatic disease (OS) were identified as independent risk factors.Conclusion: The incidence of AT/RT in children below 1 year is higher than previously reported. A subset of patients with favorable clinical risk factors profits from intensive multimodal treatment. Prospective clinical and biological studies are needed to further define prognostic factors and optimize therapy. Pediatr Blood Cancer 2011; 57: 978–985.Keywords
Funding Information
- German Children's Cancer Foundation
This publication has 38 references indexed in Scilit:
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010
- Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition SyndromeThe American Journal of Human Genetics, 2010
- High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous systemJournal of Neuro-Oncology, 2009
- Childhood Atypical Teratoid Rhabdoid Tumor of the Central Nervous SystemJournal of Pediatric Hematology/Oncology, 2009
- Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapyNeuro-Oncology, 2009
- Genomic Analysis Using High-Density Single Nucleotide Polymorphism-Based Oligonucleotide Arrays and Multiplex Ligation-Dependent Probe Amplification Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid TumorsClinical Cancer Research, 2009
- Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid TumorJournal of Clinical Oncology, 2009
- Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumorsPediatric Blood & Cancer, 2008
- Giant Supratentorial Atypical Teratoid/Rhabdoid Tumor Presentation: A Case of a Five-Year-Old Child with Favorable Outcome and Review of the LiteraturePediatric Neurosurgery, 2007
- Multicentre analysis of anthracycline‐induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93‐01/GPOH*Medical and Pediatric Oncology, 2002